FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294293444> ?p ?o ?g. }

• W4294293444 endingPage "1831" @default.
• W4294293444 startingPage "1831" @default.
• W4294293444 abstract "Zein can be utilized to form nanoscale particles for drug delivery applications. Despite the ease of synthesis, these particles often aggregate when exposed to physiologically relevant conditions (e.g., pH and salt concentrations). This instability has prevented their further development in applications requiring intravenous administration. To mitigate this colloidal instability, this research explored Zein nanoparticles (NP)s that were modified with polyethylene glycol (PEG) either through functionalized PEG pre- or post-NP formation. The results suggest that the pre-functionalization of the Zein using N-hydroxysuccinimide ester terminated PEG is the method of choice for synthesizing Zein NPs with conjugated PEG (Zein:PEG-Zein NPs). Zein:PEG-Zein NPs formed using this method displayed excellent stability in physiologically relevant conditions over 72 h and were stable at 4 °C for at least 3 months. When the NPs were cultured with cells for 72 h, no cytotoxicity or early signs of apoptosis were identified. Cellular uptake of the Zein:PEG-Zein NPs did not seem to be impacted by the amount of PEG incorporated in the NP but were concentration-, time-, and temperature-dependent. The lowest percent, stable Zein:PEG-Zein NP formulation (80% unmodified Zein and 20% PEG-modified Zein) induced no observable toxicity over 14 days in CD-1 mice dosed at 70 mg/kg via the tail vein. However, repeat dose pharmacokinetic (PK) studies demonstrated that following the first dose, the second dose caused health issues that required euthanasia shortly after administration. For those animals that survived, there was faster plasma elimination of the Zein:PEG-Zein NPs. Despite this, the Zein:PEG-Zein NPs represent a significantly improved formulation approach, one that displays a long circulation half-life and is suitable for single-use administration. Repeat dose applications will require additional methods to silence the immune response that is generated when using these NPs intravenously." @default.
• W4294293444 created "2022-09-02" @default.
• W4294293444 creator A5010054862 @default.
• W4294293444 creator A5018395984 @default.
• W4294293444 creator A5054284243 @default.
• W4294293444 creator A5063090346 @default.
• W4294293444 creator A5067087907 @default.
• W4294293444 creator A5070792731 @default.
• W4294293444 date "2022-08-31" @default.
• W4294293444 modified "2023-09-26" @default.
• W4294293444 title "PEG Conjugated Zein Nanoparticles for In Vivo Use" @default.
• W4294293444 cites W1843302206 @default.
• W4294293444 cites W1968835919 @default.
• W4294293444 cites W1970046362 @default.
• W4294293444 cites W1971511002 @default.
• W4294293444 cites W1974352115 @default.
• W4294293444 cites W1985858988 @default.
• W4294293444 cites W1990796256 @default.
• W4294293444 cites W1991533406 @default.
• W4294293444 cites W1993420633 @default.
• W4294293444 cites W2002269770 @default.
• W4294293444 cites W2013765163 @default.
• W4294293444 cites W2024182029 @default.
• W4294293444 cites W2033623607 @default.
• W4294293444 cites W2038932660 @default.
• W4294293444 cites W2050239543 @default.
• W4294293444 cites W2056726667 @default.
• W4294293444 cites W2059955514 @default.
• W4294293444 cites W2075352426 @default.
• W4294293444 cites W2094682437 @default.
• W4294293444 cites W2129181046 @default.
• W4294293444 cites W2144295892 @default.
• W4294293444 cites W2151995810 @default.
• W4294293444 cites W2219848486 @default.
• W4294293444 cites W2313305184 @default.
• W4294293444 cites W2334695928 @default.
• W4294293444 cites W2558942645 @default.
• W4294293444 cites W2575685910 @default.
• W4294293444 cites W2582916826 @default.
• W4294293444 cites W2591263903 @default.
• W4294293444 cites W2624317658 @default.
• W4294293444 cites W2727357448 @default.
• W4294293444 cites W2736247111 @default.
• W4294293444 cites W2766181274 @default.
• W4294293444 cites W2794249669 @default.
• W4294293444 cites W2862652267 @default.
• W4294293444 cites W2944868824 @default.
• W4294293444 cites W2955534363 @default.
• W4294293444 cites W2982483577 @default.
• W4294293444 cites W2992502209 @default.
• W4294293444 cites W2995069349 @default.
• W4294293444 cites W2998012028 @default.
• W4294293444 cites W3028566323 @default.
• W4294293444 cites W3040057801 @default.
• W4294293444 cites W3125908921 @default.
• W4294293444 cites W3134254717 @default.
• W4294293444 cites W4213031115 @default.
• W4294293444 cites W4280577187 @default.
• W4294293444 cites W4283701099 @default.
• W4294293444 doi "https://doi.org/10.3390/pharmaceutics14091831" @default.
• W4294293444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36145579" @default.
• W4294293444 hasPublicationYear "2022" @default.
• W4294293444 type Work @default.
• W4294293444 citedByCount "2" @default.
• W4294293444 countsByYear W42942934442023 @default.
• W4294293444 crossrefType "journal-article" @default.
• W4294293444 hasAuthorship W4294293444A5010054862 @default.
• W4294293444 hasAuthorship W4294293444A5018395984 @default.
• W4294293444 hasAuthorship W4294293444A5054284243 @default.
• W4294293444 hasAuthorship W4294293444A5063090346 @default.
• W4294293444 hasAuthorship W4294293444A5067087907 @default.
• W4294293444 hasAuthorship W4294293444A5070792731 @default.
• W4294293444 hasBestOaLocation W42942934441 @default.
• W4294293444 hasConcept C10138342 @default.
• W4294293444 hasConcept C109316439 @default.
• W4294293444 hasConcept C112613896 @default.
• W4294293444 hasConcept C112705442 @default.
• W4294293444 hasConcept C12554922 @default.
• W4294293444 hasConcept C150903083 @default.
• W4294293444 hasConcept C155672457 @default.
• W4294293444 hasConcept C162324750 @default.
• W4294293444 hasConcept C171250308 @default.
• W4294293444 hasConcept C178790620 @default.
• W4294293444 hasConcept C185592680 @default.
• W4294293444 hasConcept C192562407 @default.
• W4294293444 hasConcept C202751555 @default.
• W4294293444 hasConcept C207001950 @default.
• W4294293444 hasConcept C2776964284 @default.
• W4294293444 hasConcept C2779149719 @default.
• W4294293444 hasConcept C521977710 @default.
• W4294293444 hasConcept C54400483 @default.
• W4294293444 hasConcept C55493867 @default.
• W4294293444 hasConcept C86803240 @default.
• W4294293444 hasConcept C98274493 @default.
• W4294293444 hasConceptScore W4294293444C10138342 @default.
• W4294293444 hasConceptScore W4294293444C109316439 @default.
• W4294293444 hasConceptScore W4294293444C112613896 @default.
• W4294293444 hasConceptScore W4294293444C112705442 @default.

• next